Rigel Pharmaceuticals
RIGL
Market cap $356M

21.01 USD

+1.11

5.58%

At close Jul 30, 4:00 PM EDT

After hours

21.20

+0.19

0.90%

1 day

5.58%

5 days

-0.28%

1 month

12.17%

3 months

7.41%

6 months

-7.04%

Year to date

21.30%

1 year

97.46%

5 years

-13.18%

10 years

-25.76%

About: Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Employees: 164

Healthcare Biotechnology

0

Funds holding %

of 7,323 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

85% more call options, than puts

Call options by funds: $643K | Put options by funds: $348K

23% more capital invested

Capital invested by funds: $203M [Q4 2024] → $250M (+$47.1M) [Q1 2025]

16% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 38

9.26% more ownership

Funds ownership: 68.59% [Q4 2024] → 77.84% (+9.26%) [Q1 2025]

10% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 21

1% more funds holding

Funds holding: 122 [Q4 2024] → 123 (+1) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$23

9%

upside

Avg. target

$23

9%

upside

High target

$23

9%

upside

1 analyst rating

0 positive

0%

1 neutral

100%

0 negative

0%

Cantor Fitzgerald

Kristen Kluska

9%upside

$23

Neutral

Maintained

7 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about RIGL published over the past 30 days

Zacks Investment Research

Why Rigel (RIGL) Could Beat Earnings Estimates Again

Rigel (RIGL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Rigel (RIGL) Could Beat Earnings Estimates Again

Zacks Investment Research

Can Rigel (RIGL) Climb 69.55% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 69.6% in Rigel (RIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Rigel (RIGL) Climb 69.55% to Reach the Level Wall Street Analysts Expect?

Zacks Investment Research

Are Investors Undervaluing Rigel Pharmaceuticals (RIGL) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Rigel Pharmaceuticals (RIGL) Right Now?

Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif. , July 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2025 financial results after market close on Tuesday, August 5, 2025.

Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , July 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Zacks Investment Research

Is Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now?

Zacks Investment Research

Wall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High?

The consensus price target hints at a 72% upside potential for Rigel (RIGL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High?

Rigel to Present at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , May 28, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 12:50 p.m.

Rigel to Present at the Jefferies Global Healthcare Conference

Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors Supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AML SOUTH SAN FRANCISCO, Calif. , May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced seven upcoming poster presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2025 Congress.

Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

Zacks Investment Research

Here's Why Rigel (RIGL) Is a Great 'Buy the Bottom' Stock Now

Rigel (RIGL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here's Why Rigel (RIGL) Is a Great 'Buy the Bottom' Stock Now

See News Rankings

Charts implemented using Lightweight Charts™